Alaska Opioid Lawsuit Against Albertsons and Kroger Revived: State Supreme Court Reinstates Nuisance Claim
On Nov. 6, 2026, a unanimous Alaska Supreme Court reversed the 2024 dismissal of Alaska's opioid lawsuit against Albertsons and Kroger, holding the State stated a public nuisance claim and keeping one slice of its consumer-protection case alive.
Torts Desk··12 min read

The Alaska opioid lawsuit against Albertsons and Kroger is back on track: on Friday, Nov. 6, 2026, the Alaska Supreme Court unanimously reversed a 2024 trial-court dismissal and held that the State adequately alleged the pharmacy chains created a public nuisance by failing to meet their legal obligations when dispensing opioids. The decision, State v. Albertsons Companies, Inc., No. S-19048, sends the nuisance claim and a narrow piece of the State's Unfair Trade Practices Act claim back to Anchorage Superior Court, where Albertsons (owner of Safeway and Carr-Gottstein) and Kroger (owner of Fred Meyer) will now have to defend the case on the merits.
The ruling is a pleading-stage win, not a liability finding. But it matters well beyond Alaska. It puts a state high court squarely behind the broad Restatement view of public nuisance in pharmacy opioid litigation after the Oklahoma and Ohio supreme courts went the other way, and it arrived one day after a Washington judge ordered Albertsons to pay $900 million in a parallel case. For a defendant that announced a $774 million national settlement framework in April, the week has shown how expensive the holdout states can be.
What did the Alaska Supreme Court decide in the opioid lawsuit against Albertsons and Kroger?
The court reversed Superior Court Judge Una Gandbhir's decision to dismiss the State's case in its entirety and remanded for further proceedings. Writing for a unanimous court in a 35-page opinion, Justice Jude Pate held: "we hold that the pharmacies' failure to fulfill their legal obligations when dispensing opioids unreasonably interfered with public rights protected by the common law."
Three holdings carry the decision:
- Public nuisance survives. The State "adequately alleged that the pharmacies unreasonably interfered with public rights," and plausibly alleged interference with the collective right to public health and public safety. That is enough to state a claim at the motion-to-dismiss stage.
- No product-sale exception. The court declined to adopt a categorical rule barring public nuisance claims that relate to the sale of products when the alleged conduct otherwise satisfies Alaska nuisance law. It also said Alaska recognizes public nuisance both at common law and by statute, and that neither framework limits the tort to property-related harms.
- Consumer-protection claim mostly fails, with one exception. Most of the alleged failures in dispensing, due diligence and reporting fall within the regulatory exemption of the Unfair Trade Practices and Consumer Protection Act (UTPA), because the Board of Pharmacy and state controlled-substance rules govern that conduct. The exception is the State's allegation that the chains deceptively promoted their compliance efforts: "We hold that the pharmacies failed to meet their burden to establish that the alleged deceptive promotion of their compliance efforts was exempt."
In short, the State goes back to the trial court with a full public nuisance claim and a trimmed UTPA claim aimed at advertising, not dispensing.
Timeline of the Alaska opioid case
| Date | Event |
|---|---|
| December 2022 | Alaska Department of Law sues Walgreens, Walmart, Albertsons and Kroger in Anchorage Superior Court, pleading public nuisance and UTPA violations |
| December 2022 | State announces settlements including about $8.5 million from Walmart; Walgreens later settles as well |
| March 4, 2024 | Judge Una Gandbhir dismisses the claims against Albertsons and Kroger, holding Alaska law does not support the nuisance theory and the UTPA exemption applies |
| February 2025 | Alaska Supreme Court hears oral argument |
| April 14, 2026 | Albertsons announces a $774 million national opioid settlement framework |
| Nov. 5, 2026 | Washington judge orders Albertsons to pay $900 million after a bench trial |
| Nov. 6, 2026 | Alaska Supreme Court reverses the dismissal in State v. Albertsons Companies, Inc. |
| Next | Remand to Anchorage Superior Court for discovery and further proceedings |
The roughly 21-month gap between oral argument and decision is long even by state high-court standards, and it suggests the justices worked carefully through a question other courts have split on.
Why was Alaska's opioid lawsuit against the pharmacies dismissed in 2024?
Judge Gandbhir's March 2024 order took the defendants' central position: that misuse of a lawful product, even one that harms many people, does not interfere with a right common to the general public. She called the State's theory "a bridge too far." She also held that the UTPA did not reach the alleged conduct because pharmacies are heavily regulated, an argument Kroger's counsel pressed again on appeal by telling the justices that none of the alleged acts fall outside the regulations that govern pharmacies.
At argument in February 2025, the State countered that the harms of the opioid epidemic fall on whole communities, not just individual patients, which is the defining feature of a public, rather than private, wrong. The justices tested both sides. According to Courthouse News, Justice Dario Borghesan observed that the State's alleged harms involved more degrees of separation than a typical public nuisance claim. The final opinion resolved that concern in the State's favor at the pleading stage, while leaving causation to be proved.
Can a state sue a pharmacy for public nuisance over opioids?
In Alaska, yes: the State can bring a public nuisance claim against a pharmacy for opioid dispensing, provided it alleges conduct that unreasonably interferes with a public right. The court anchored its analysis in the Restatement (Second) of Torts, under which an interference with a public right can be unreasonable based on several non-exclusive factors, including whether the conduct significantly interferes with public health or safety, whether it is proscribed by statute or regulation, and whether it is of a continuing nature that the actor knows has a significant effect on the public.
That framework fits the State's theory closely. Pharmacies dispensing controlled substances operate under a "corresponding responsibility" to ensure that prescriptions are issued for a legitimate medical purpose, a federal duty set out in the Controlled Substances Act regulations and echoed in state law. The State's complaint alleges that the chains filled prescriptions bearing unresolved red flags and failed to maintain adequate systems to prevent diversion. A pleaded breach of a statutory or regulatory duty, combined with allegations of widespread public-health harm, satisfies two Restatement factors on its face.
The court's refusal to adopt a product-sale bar is the doctrinal headline. Defendants and their amici, including a U.S. Chamber of Commerce coalition, asked the court to hold that selling a lawful, regulated product cannot be a public nuisance, because otherwise nuisance law swallows product liability. The court disagreed with that categorical framing. It distinguished Oklahoma explicitly, writing that "unlike the Oklahoma Supreme Court, we have never taken so narrow a view" that public nuisance always requires "criminal or property-based conduct."
Two limits deserve emphasis. First, the claim rests on the pharmacies' alleged failure to fulfill their legal obligations, not on the mere act of selling opioids. Second, the holding is that the State plausibly alleged a nuisance. The State must still prove unreasonable interference, causation and an appropriate remedy.
Which parts of Alaska's Unfair Trade Practices Act claim survived?
Only the advertising theory survived. The UTPA exempts acts or transactions regulated under laws administered by the state or a federal regulatory agency, and the court read that exemption to cover most of what the State challenged: how the pharmacies dispensed, documented, investigated and reported opioid prescriptions. Those functions sit under the Board of Pharmacy's ongoing regulation and the state's controlled-substance scheme, so they cannot also be pursued as unfair trade practices.
The State's other allegation is different in kind. It alleges that Albertsons and Kroger ran advertising and public messaging designed to persuade Alaskans that the companies were following the law and helping fight the opioid epidemic. The Board of Pharmacy does not regulate that kind of corporate promotion, and the court placed the burden of proving the exemption on the party claiming it. The pharmacies did not carry that burden, so the deceptive-promotion claim goes forward.
| Claim | Trial court (March 2024) | Alaska Supreme Court (Nov. 6, 2026) | Status on remand |
|---|---|---|---|
| Public nuisance (dispensing failures) | Dismissed | Reversed: claim adequately alleged | Proceeds in full |
| UTPA: dispensing, due diligence, reporting | Dismissed as exempt | Affirmed: regulated by Board of Pharmacy | Out of the case |
| UTPA: deceptive promotion of compliance efforts | Dismissed as exempt | Reversed: exemption not established | Proceeds |
| Product-sale bar to nuisance | Effectively adopted | Rejected as a categorical rule | Not available as a defense |
The UTPA split matters for remedies. Alaska's consumer-protection statute carries civil penalties, and a surviving penalty claim gives the State a monetary lever that does not depend on the outcome of the equitable nuisance remedy. Washington used exactly that structure against Albertsons this month.
How does the Alaska opioid ruling compare with Oklahoma and Ohio?
Alaska now sits on the plaintiff-friendly side of a clear split among state high courts on whether public nuisance reaches the sale or dispensing of lawful opioids.
| Court | Decision | Defendant(s) | Result |
|---|---|---|---|
| Oklahoma Supreme Court (2021) | State ex rel. Hunter v. Johnson & Johnson | Manufacturer | Reversed a $465 million abatement judgment; nuisance does not extend to manufacturing, marketing and selling products |
| Supreme Court of Ohio (Dec. 10, 2024) | Certified question from the opioid MDL | CVS, Walgreens, Walmart | Ohio Product Liability Act abrogates common-law nuisance claims from product sales, undercutting a roughly $650.9 million county abatement award |
| Alaska Supreme Court (Nov. 6, 2026) | State v. Albertsons Companies, Inc. | Albertsons, Kroger | No categorical product-sale bar; nuisance claim tied to dispensing obligations proceeds |
| Washington trial court (Nov. 5, 2026) | State v. Albertsons (King County) | Albertsons, Safeway | $900 million judgment after bench trial; appeal possible |
The Ohio result turned on a statute, not on common-law first principles, so it says little about states without an equivalent abrogation provision. Oklahoma is the true doctrinal opposite, and Alaska chose to distinguish it by name. Defense counsel will now argue that Alaska's ruling is limited to conduct that breaches a specific regulatory duty; plaintiffs will cite it for the broader proposition that the sale of a regulated product is not a safe harbor from public nuisance law.
How does the Alaska ruling relate to Albertsons' $900 million Washington opioid judgment?
The two cases are separate, but they share a defendant, a theory and a timing that defense counsel cannot ignore. On Nov. 5, 2026, King County Superior Court Judge Janet Helson ordered Albertsons and Safeway to pay Washington $900 million, comprising $800 million in abatement and $100 million in Consumer Protection Act penalties, after a nine-week bench trial. Washington had declined Albertsons' April 2026 national framework, which the company valued at $774 million.
Alaska's case against Albertsons and Kroger was dismissed before either company's national deal took shape, and public reporting on the Nov. 6 decision does not say whether Alaska or its subdivisions have signed on to the Albertsons framework or to Kroger's earlier national settlement, which Kroger has described as up to $1.2 billion for states and subdivisions plus $36 million for tribes. The State's decision to keep litigating against both companies through a two-year appeal indicates that, at least as to its own sovereign claims, Alaska has chosen the litigation track. Combined with Washington's result, the Alaska decision gives other holdout jurisdictions two fresh data points: a pleading-stage ruling that the theory is viable and a trial judgment showing what it can be worth.
What happens next in Alaska's opioid case against Safeway and Fred Meyer?
The case returns to Anchorage Superior Court for discovery and, unless it settles, trial. Before that, the defendants may ask the Alaska Supreme Court to reconsider; Alaska appellate rules allow a petition for rehearing within a short window after an opinion issues. Because the decision rests on Alaska common law and the Alaska UTPA, there is no obvious federal question for U.S. Supreme Court review.
On remand, expect the fight to move to the issues the Supreme Court left open:
- Causation. The State must connect each chain's dispensing conduct to the public-health harms it alleges, the "degrees of separation" problem raised at argument.
- Remedy. Abatement is equitable and is typically decided by the court. Washington's $800 million abatement trust and its alternative civil penalty offer a template the State may follow.
- The surviving UTPA claim. Discovery into the chains' public statements about their opioid compliance programs will now be relevant, and so will the penalty exposure tied to that claim.
- Settlement. Walmart and Walgreens settled before the dismissal. Albertsons and Kroger now face renewed exposure in Alaska alongside Washington's judgment.
The Department of Law said in a written statement that it was pleased the court agreed the case can proceed based on the companies' alleged wrongful conduct. Reporting indicates the companies were still reviewing the decision.
Does the Alaska ruling mean Albertsons and Kroger are liable?
No. The Alaska Supreme Court decided only that the State's complaint states a claim. It took the State's factual allegations as true, as courts must at the motion-to-dismiss stage, and held that those allegations, if proved, would amount to an unreasonable interference with public rights. Neither chain has been found to have caused or contributed to Alaska's opioid crisis, and both deny wrongdoing. No damages, penalties or abatement have been ordered in Alaska.
What it means for state AGs, pharmacy defendants and the plaintiffs' bar
For state attorneys general. The decision is a ready citation for any state still litigating against a pharmacy chain under common-law nuisance. It also models a pleading strategy: tie the nuisance theory to breached regulatory duties, and plead a separate deceptive-promotion claim that sits outside a consumer-protection statute's regulatory exemption.
For pharmacy and retail defendants. The categorical product-sale defense is gone in Alaska. Defense efforts will shift to causation, the scope of abatement, and the line between regulated dispensing and unregulated marketing. Corporate statements about opioid compliance programs are now potential evidence, not just public relations.
For plaintiffs' firms on state mandates. Outside counsel retained on a Contingency Fee by state AGs gain leverage in settlement talks with Albertsons and Kroger, two defendants that have chosen to fight in some holdout states. The Washington judgment shows the upside; the Alaska ruling shows the path past a motion to dismiss.
For other public nuisance dockets. Governments pursuing nuisance theories over PFAS, social media and other products will cite Alaska's refusal to bar product-related nuisance claims. Defendants in those cases will answer with Oklahoma and Ohio. Every Mass Tort built on a government nuisance theory now has one more high-court opinion in the plaintiffs' column, along with the reminder that the Restatement test still demands proof of unreasonable interference with a right common to the public.
Frequently asked questions
What is State v. Albertsons Companies, Inc.?
It is the State of Alaska's opioid lawsuit against Albertsons Companies (Safeway, Carr-Gottstein) and Kroger (Fred Meyer), filed in Anchorage Superior Court in December 2022. The Alaska Supreme Court decided the appeal, No. S-19048, on Nov. 6, 2026.
Who wrote the Alaska Supreme Court opioid opinion?
Justice Jude Pate wrote the opinion for a unanimous court.
Did the court say pharmacies can be sued for selling opioids?
Not for selling opioids as such. The court held that the State may pursue a public nuisance claim based on the pharmacies' alleged failure to fulfill their legal obligations when dispensing opioids, and it refused to create a blanket exception for claims involving product sales.
Why didn't the State's full consumer-protection claim survive?
Because the UTPA exempts conduct regulated by state agencies, and the Board of Pharmacy regulates dispensing, due diligence and reporting. Only the allegation that the companies deceptively promoted their compliance efforts survived.
Is this case part of an opioid MDL?
No. It is a state-court case brought by the State of Alaska, separate from the federal opioid Multidistrict Litigation (MDL) in Ohio.
Has Alaska settled with any other pharmacies?
Yes. Walmart and Walgreens, originally named in the same suit, settled with the State; the Department of Law reported Walmart's share at about $8.5 million.
Published for legal professionals. Analysis and summaries only — not legal advice, and no attorney-client relationship is created by use of this site.
Read next

Albertsons Opioid Ruling: Washington Judge Orders $900 Million After Nine-Week Bench Trial
On Nov. 5, 2026, King County Superior Court Judge Janet Helson ordered Albertsons and Safeway to pay Washington $900 million: $800 million in abatement and $100 million in Consumer Protection Act penalties. It is the first opioid judgment against the chain and believed to be the largest verdict in state history.
Torts Desk · 12 min

Albertsons Opioid Trial in Washington Ends: State Asks for $2.2 Billion in Abatement
Closing arguments in mid-September 2026 ended a two-month bench trial in King County Superior Court. Washington wants roughly $2.2 billion from Albertsons and Safeway as their share of a $44.4 billion abatement plan, and Judge Janet Helson, not a jury, will decide.
Torts Desk · 11 min

The Sixth Circuit PBM Opioid Ruling Pulls Kentucky Into Federal Court as Polster Defends 800 Claims
In 24 hours the Sixth Circuit reversed the remand of Kentucky's pharmacy benefit manager opioid suit and took delivery of Judge Dan Polster's answer to a mandamus petition that would strip roughly 800 amended complaints out of MDL 2804. The forum fight and the aggregation fight are now in the same courthouse.
Courts Desk · 12 min